IP Library › Granted Patent US 12,433,264
Granted Patent B2
US 12,433,264 · App. 17/031,367 · Granted Oct 7, 2025

Non-human animals having an engineered immunoglobulin lambda light chain locus

Inventors: Chunguang Guo (Thornwood, NY); Faith Harris (Mamaroneck, NY); Vera Voronina (Sleepy Hollow, NY); John McWhirter (Hastings-on-Hudson, NY); Natasha Levenkova (New York, NY); Lynn Macdonald (Harrison, NY); Naxin Tu (Pleasantville, NY); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A01K67/0278C07K16/00C12N15/907A01K2207/15A01K2217/05A01K2217/072A01K2217/075A01K2227/105A01K2267/01C07K2317/14C07K2317/24C12N2015/8518C12N2800/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,264
App. No.
17/031,367
Granted
Oct 7, 2025
Kind
B2
Abstract

Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non-human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Igλ light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Igλ light chains, in whole or in part, that are encoded by human Igλ light chain-encoding sequences inserted into an endogenous Igλ light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.

Claims (32)

1. A method of producing an antibody, the method comprising:

(a) immunizing a genetically modified mouse with an antigen of interest, which genetically modified mouse has a germline genome comprising an engineered endogenous immunoglobulin λ light chain locus comprising:

(i) one or more human Vλ gene segments,

(ii) one or more human Jλ gene segments, and

(iii) one or more human Cλ gene segments,

wherein (i) and (ii) are operably linked to (iii) and a mouse Cλ gene segment, and wherein the engineered endogenous immunoglobulin λ light chain locus further comprises one or more mouse immunoglobulin λ light chain enhancers (Eλ) and one or more human immunoglobulin λ light chain enhancers (Eλ);

(b) maintaining the genetically modified mouse under conditions sufficient for the genetically modified mouse to produce an immune response to the antigen of interest; and

(c) recovering an antibody from the genetically modified mouse, or a cell thereof, wherein the antibody:

(i) is capable of binding the antigen of interest, and

(ii) comprises an immunoglobulin λ light chain comprising a human λ variable domain and either a human λ constant domain or a mouse λ constant domain.

2. The method of claim 1 , wherein the engineered endogenous immunoglobulin light chain locus comprises two mouse Eλs.

3. The method of claim 2 , wherein the two mouse Eλs are a mouse Eλ and a mouse Eλ3-1.

4. The method of claim 1 , wherein the engineered endogenous immunoglobulin λ light chain locus comprises three human Eλs.

5. The method of claim 1 , wherein the germline genome of the genetically modified mouse further comprises:

(i) an engineered endogenous immunoglobulin heavy chain locus comprising insertion of one or more human V H gene segments, one or more human D H gene segments, and one or more human J H gene segments, which human V H , D H and J H gene segments are operably linked to a mouse immunoglobulin heavy chain constant region; or

(ii) an engineered endogenous immunoglobulin heavy chain locus comprising insertion of one or more human V H gene segments, one or more human D H gene segments, and one or more human J H gene segments, which human V H , D H and J H gene segments are operably linked to a mouse immunoglobulin heavy chain constant region, and an engineered endogenous immunoglobulin κ light chain locus comprising insertion of one or more human Vκ gene segments and one or more human Jκ gene segments, which human Vκ and Jκ gene segments are operably linked to a mouse immunoglobulin Cκ region.

6. The method of claim 5 , wherein the insertion of one or more human V H gene segments, one or more human D H gene segments and one or more human J H gene segments replace endogenous mouse V H , D H , and J H gene segments.

7. The method of claim 6 , wherein the insertion includes human non-coding DNA that naturally appears between human V H gene segments, human D H gene segments, human J H gene segments, or combinations thereof.

8. The method of claim 5 , wherein the insertion of one or more human Vκ gene segments and one or more human Jκ gene segments replace endogenous mouse Vκ and Jκ gene segments.

9. The method of claim 8 , wherein the insertion includes human non-coding DNA that naturally appears between human Vκ gene segments, human Jκ gene segments, or combinations thereof.

10. The method of claim 5 , wherein the mouse immunoglobulin heavy chain constant region is an endogenous mouse immunoglobulin heavy chain constant region.

11. The method of claim 5 , wherein the mouse immunoglobulin Cκ region is an endogenous mouse Cκ region.

12. The method of claim 1 , wherein the engineered endogenous immunoglobulin λ light chain locus comprises a deletion of endogenous Vλ and Jλ gene segments, in whole or in part.

13. The method of claim 1 , wherein the mouse Cλ gene segment is a mouse Cλ1 gene segment.

14. The method of claim 5 , wherein the engineered endogenous immunoglobulin κ light chain locus comprises insertion of the proximal Vκ duplication, in whole or in part, of a human immunoglobulin κ light chain locus.

15. The method of claim 5 , wherein the engineered endogenous immunoglobulin heavy chain locus lacks an endogenous mouse Adam6 gene.

16. The method of claim 15 , wherein the engineered endogenous immunoglobulin heavy chain locus further comprises insertion of one or more nucleotide sequences encoding one or more mouse Adam6 polypeptides.

17. The method of claim 5 , wherein the genetically modified mouse is homozygous for the engineered endogenous immunoglobulin heavy chain locus.

18. The method of claim 5 , wherein the genetically modified mouse is homozygous for the engineered endogenous immunoglobulin k light chain locus.

19. The method of claim 1 , wherein the genetically modified mouse is homozygous for the engineered endogenous immunoglobulin λ light chain locus.

20. The method of claim 1 , wherein the cell of the genetically modified mouse is a B cell.

21. The method of claim 20 , further comprising producing a hybridoma from the B cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2020
From: GUO, CHUNGUANG; HARRIS, FAITH; VORONINA, VERA; MCWHIRTER, JOHN; LEVENKOVA, NATASHA; MACDONALD, LYNN; TU, NAXIN; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 054526/0016 →
Continuity (4)
Division 15803513 · Nov 3, 2017
Provisional Application 62567932 · Oct 4, 2017
Provisional Application 62417845 · Nov 4, 2016
Related Publication 20210029978A1 · Feb 4, 2021
References Cited (118)
US 5670356A · Sherf et al. · 1997 [cited by applicant]
US 5874304A · Zolotukhin et al. · 1999 [cited by applicant]
US 6586251B2 · Economides et al. · 2003 [cited by applicant]
US 6596541B2 · Murphy et al. · 2003 [cited by applicant]
US 6998514B2 · Bruggemann · 2006 [cited by applicant]
US 7105348B2 · Murphy et al. · 2006 [cited by applicant]
US 7435871B2 · Green et al. · 2008 [cited by applicant]
US 8502018B2 · Murphy et al. · 2013 [cited by applicant]
US 8642835B2 · MacDonald et al. · 2014 [cited by applicant]
US 8697940B2 · Macdonald et al. · 2014 [cited by applicant]
US 8791323B2 · Murphy et al. · 2014 [cited by applicant]
US 9006511B2 · Macdonald et al. · 2015 [cited by applicant]
US 9012717B2 · Macdonald et al. · 2015 [cited by applicant]
US 9029628B2 · Macdonald et al. · 2015 [cited by applicant]
US 9035128B2 · MacDonald et al. · 2015 [cited by applicant]
US 9066502B2 · Macdonald et al. · 2015 [cited by applicant]
US 9150662B2 · Macdonald et al. · 2015 [cited by applicant]
US 9163092B2 · Macdonald et al. · 2015 [cited by applicant]
US 9228208B2 · Frendewey et al. · 2016 [cited by applicant]
US 10820582B2 · Guo et al. · 2020 [cited by applicant]
US 20020088016A1 · Bruggemann · 2002 [cited by applicant]
US 20030217373A1 · Green et al. · 2003 [cited by applicant]
US 20110236378A1 · Green et al. · 2011 [cited by applicant]
US 20120204278A1 · Bradley · 2012 [cited by examiner]
US 20130096087A1 · Van Der Beek et al. · 2013 [cited by applicant]
US 20130160153A1 · Macdonald et al. · 2013 [cited by applicant]
US 20140235933A1 · Lee et al. · 2014 [cited by applicant]
US 20140245468A1 · McWhirter et al. · 2014 [cited by applicant]
US 20140283150A1 · Bradley · 2014 [cited by examiner]
US 20150159174A1 · Frendewey et al. · 2015 [cited by applicant]
US 20150376628A1 · Schoenherr et al. · 2015 [cited by applicant]
US 20150376650A1 · Auerbach et al. · 2015 [cited by applicant]
US 20160060657A1 · Frendewey et al. · 2016 [cited by applicant]
US 20160177339A1 · Voronina et al. · 2016 [cited by applicant]
US 20180125043A1 · Guo et al. · 2018 [cited by applicant]
AU 2012323987A1 · 2013 [cited by applicant]
CN 104334732A · 2015 [cited by applicant]
CN 104994730A · 2015 [cited by applicant]
EP 2421357A1 · 2012 [cited by applicant]
EP 3407709B1 · 2020 [cited by applicant]
JP 2015512634A · 2015 [cited by applicant]
KR 1020150118135A · 2015 [cited by applicant]
RU 2425880C2 · 2011 [cited by applicant]
WO WO2002036789A2 · 2002 [cited by applicant]
WO WO2002066630 · 2002 [cited by examiner]
WO WO2011004192 · 2011 [cited by applicant]
WO WO2011163311A1 · 2011 [cited by applicant]
WO WO2013061098A2 · 2013 [cited by applicant]
WO WO2013096142A1 · 2013 [cited by applicant]
WO WO2013144566A2 · 2013 [cited by applicant]
WO WO2015049517A2 · 2015 [cited by examiner]
WO WO2018128691A1 · 2018 [cited by applicant]
Choi et al. (2004, Genomics, vol. 83, pp. 636-646) (Year: 2004). [cited by examiner]
Altschul, S.F. and Gish, W., Local alignment statistics. Methods Enzymol, 266:460-80 (1996). [cited by applicant]
Altschul, S.F. et al., Basic local alignment search tool, J Mol Biol, 215(3):403-10 (1990). [cited by applicant]
Altschul, S.F. et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Res, 25(17):3389-402 (1997). [cited by applicant]
Araki, K. et al., Site-specific recombination of a transgene in fertilized eggs by transient expression of Cre recombinase, Proc Natl Acad Sci USA, 92(1):160-4 (1995). [cited by applicant]
Asenbauer, H. and Klobeck, H.G., Tissue-specific deoxyribonuclease I-hypersensitive sites in the vicinity of the immunoglobulin C lambda cluster of man, Eur J Immunol, 26(1):142-50 (1996). [cited by applicant]
Auerbach, W. et al., Establishment and chimera analysis of 129/SvEv- and C57BL/6-derived mouse embryonic stem cell lines, Biotechniques, 29(5):1024-8, 1030, 1032 (2000). [cited by applicant]
Azzazy, H.M. and Highsmith, W.E. Jr., Phage display technology: clinical applications and recent innovations, Clin Biochem, 35(6):425-45 (2002). [cited by applicant]
Barthold, Stephen W., Genetically altered mice: phenotypes, no phenotypes, and Faux phenotypes, Genetica, 122:75-88 (2004). [cited by applicant]
Bruggemann, M. et al., A repertoire of monoclonal antibodies with human heavy chains from transgenic mice, Proc. Natl. Acad. Sci. USA, 86: 6709-6713, 1989. [cited by applicant]
Bruggemann, M. et al., Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus, Eur J Immunol, 21(5):1323-1326 (1991). [cited by applicant]
Davies, N. et al., Creation of Mice Expressing Human Antibody Light Chains by Introduction of a Yeast Artificial Chromosome Containing the Core Region of the Human Immunoglobulin κLocus, Nature Biotechnology 11:911-914,… [cited by applicant]
Dechiara, T.M. et al., Producing fully ES cell-derived mice from eight-cell stage embryo injections, Methods Enzymol, 476:285-94 (2010). [cited by applicant]
Dechiara, T.M. et al., VelociMouse: fully ES cell-derived F0-generation mice obtained from the injection of ES cells into eight-cell-stage embryos, Methods Mol Biol, 530:311-24 (2009). [cited by applicant]
Dunham, I. et al., The DNA sequence of human chromosome 22, Nature, 402(6761):489-95 (1999). [cited by applicant]
Dymecki, S.M., Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice, Proc Natl Acad Sci USA, 93(12):6191-6 (1996). [cited by applicant]
Festing, M.F. et al., Revised nomenclature for strain 129 mice, Mamm Genome, 10(8):836 (1999). [cited by applicant]
Fishwild, D.M. et al., High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice, Nat Biotechnol, 14(7):845-51 (1996). [cited by applicant]
Frendewey, D. et al., The loss-of-allele assay for ES cell screening and mouse genotyping, Methods Enzymol, 476:295-307 (2010). [cited by applicant]
Garcia-Arocena, D., Same Mutation, Different Phenotype?, The Jackson Laboratory, 5 pages (2014). [cited by applicant]
Gavilondo, J.V. and Larrick, J.W., Antibody engineering at the millennium, Biotechniques, 29(1):128-32 (2000). [cited by applicant]
Glassy, M. et al., Final Oral Progamme, The Twelfth International Conference on Human Antibodies & Hybridomas, 4 pages (May 10-12, 2006). [cited by applicant]
Glassy, M. et al., Second Circular and Provisional Conference Program, The Twelfth International Conference on Human Antibodies & Hybridomas, 8 pages (May 10-12, 2006). [cited by applicant]
Gonnett, G.H. et al., Exhaustive matching of the entire protein sequence database, Science, 256(5062):1443-5 (1992). [cited by applicant]
Green, L. et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nature Genetics, 7(1):13-21 (1994). [cited by applicant]
Green, L. et al., Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes, J. Exp. Med., 188(3):483-495 (1998). [cited by applicant]
Gu, H. et al., Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-IoxP-mediated gene targeting, Cell, 73(6):1155-64 (1993). [cited by applicant]
Heimain-Patterson, T. et al., Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: A window of opportunity in the search for genetic modifiers, Amyotrophic L… [cited by applicant]
Hong, J. et al., Derivation and Characterization of Embryonic Stem Cells Lines Derived from Transgenic Fischer 344 and Dark Agouti Rats, Stem Cells and Development, 21(9):1571-1586 (2012). [cited by applicant]
Hoogenboom, H.R., Designing and optimizing library selection strategies for generating high-affinity antibodies, Trends Biotechnol, 15(2):62-70 (1997). [cited by applicant]
Hoogenboon, H.R. and Chames, P., Natural and designer binding sites made by phage display technology, Immunol Today, 21(8):371-8 (2000). [cited by applicant]
International Search Report for PCT/US2017/060006 (Non-Human Animals Having an Engineered Immunoglobulin Lambda Light Chain Locus, filed Nov. 3, 2017), issued by ISA/EP, 7 pages (Jun. 19, 2018). [cited by applicant]
Jakobovits, A. et al., Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs, Ann NY Acad Sci, 764:525-35 (1995). [cited by applicant]
Karow, Margaret, Making the VelocImmune mouse using Velocigene technology [abstract], Session 5: Molecular biology—II, Human Antibodies, 15:19-28 (2006). [cited by applicant]
Kellermann, S.A. and Green, L.L., Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics, Curr Opin Biotechnol, 13(6):593-7 (2002). [cited by applicant]
Kim, U.J. et al., Construction and characterization of a human bacterial artificial chromosome library, Genomics, 34(2):213-8 (1996). [cited by applicant]
Lakso, M. et al., Targeted oncogene activation by site-specific recombination in transgenic mice, Proc Natl Acad Sci USA, 89(14):6232-6 (1992). [cited by applicant]
Lee, E.C. et al., Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery, Nat Biotechnol, 32(4):356-363 (2014). [cited by applicant]
Little, M. et al., Of mice and men: hybridoma and recombinant antibodies, Immunol Today, 21(8):364-70 (2000). [cited by applicant]
Lonberg, N. et al., Antigen-specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications, Nature, 368:856-859, (1994). [cited by applicant]
Macdonald, L.E. et al., Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes, Proc Natl Acad Sci USA, 111(14):5147-52 (2014). [cited by applicant]
Mendez M.J., et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nat Genet. 15(2):146-56 (1997). [cited by applicant]
Moraes, J. et al., Genomic EcoRI polymorphism and cosmid sequencing reveal an insertion/deletion and a new IGLV5 allele in the human immunoglobulin lambda variable locus (22q11.2/IGLV), Immunogenetics, 55(1):10-5 (2003). [cited by applicant]
Murphy, A.J. et al., Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA, 111(14):5153-5158 (2014). [cited by applicant]
Murphy, Andrew, Making the VelocImmune Mouse Using VelociGene Technology, Human Antibodies & Hybridomas, 31 pages (May 10-12, 2006). [cited by applicant]
Nicholson, I.C. et al., Antibody Repertoires of Four- and Five-Feature Translocus Mice Carrying Human Immunoglobulin Heavy Chain and kappa and lambda light chain Yeast Artificial Chromosomes. Journal of Immunology 163(1… [cited by applicant]
O'Gorman, S. et al., Recombinase-mediated gene activation and site-specific integration in mammalian cells, Science, 251(4999):1351-5 (1991). [cited by applicant]
Orban, P.C. et al., Tissue- and site-specific DNA recombination in transgenic mice, Proc Natl Acad Sci USA, 89(15):6861-5 (1992). [cited by applicant]
Osborn, M.J. et al., High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region, J Immunol, 190(4):1481-90 (2013). [cited by applicant]
Osoegawa, K. et al., A bacterial artificial chromosome library for sequencing the complete human genome, Genome Res, 11(3):483-96 (2001). [cited by applicant]
Osoegawa, K. et al., An improved approach for construction of bacterial artificial chromosome libraries, Genomics, 52(1):1-8 (1998). [cited by applicant]
Popov, A.V. et al., Assembly and extension of yeast artificial chromosomes to build up a large locus, Gene, 177(1-2):195-201 (1996). [cited by applicant]
Popov, et al., A Human Immunoglobulin I locus is Similarly Well Expressed in Mice and Humans, J. Exp. Med., 189(10):1611-1619(1999). [cited by applicant]
Poueymirou, W.T. et al., F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses, Nat Biotechnol, 25(1):91-9 (2007). [cited by applicant]
Rajewsky, K. et al., Conditional gene targeting, J Clin Invest, 98(3):600-3 (1996). [cited by applicant]
Shizuya, H. et al., Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in [cited by applicant]
Swiatek, P.J. and Gridley, T., Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox20, Genes Dev, 7(11):2071-84 (1993). [cited by applicant]
Taylor L.D. et al., Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM, Int Immunol. 6(4):579-91 (1994). [cited by applicant]
Taylor, L.D. et al., A Transgenic Mouse that Expresses a Diversity of Human Sequence Heavy and Light Chain Immunoglobulins, Nucleic Acid Research, 20(23):6287-6295 (1992). [cited by applicant]
Tong, C. et al., Production of p53 gene knockout rats by homologous recombination in embryonic stem cells, Nature, 467:211-215 (2010). [cited by applicant]
Valenzuela, D.M., et al., High-throughput engineering of the mouse genome coupled with high-resolution expression analysis, Nat Biotechnol, 21(6):652-9 (2003). [cited by applicant]
Wagner S.D. et al., The diversity of antigen-specific monoclonal antibodies from transgenic mice bearing human immunoglobulin gene miniloci, Eur J Immunol. 24(11):2672-81 (1994). [cited by applicant]
Wagner, S.D. et al., Antibody expression from the core region of the human IgH locus reconstructed in transgenic mice using bacteriophage P1 clones, Genomics, 35(3):405-14 1996). [cited by applicant]
Written Opinion for PCT/US2017/060006 (Non-Human Animals Having an Engineered Immunoglobulin Lambda Light Chain Locus, filed Nov. 3, 2017), issued by ISA/EP, 7 pages (Jun. 19, 2018). [cited by applicant]
Xian, J. et al., Comparison of the Performance of a Plasmid-Based Human Igκ Minilocus and Yac-Based Human Igκ Transloci for the Production of Human Antibody Repertoires in Transgenic Mice, Transgenics, 2:333-343 (1998). [cited by applicant]
Syeda, F.Y. et al., The E(3-1) enhancer is essential for V(D)J recombination of the murine immunoglobulin lambda light chain locus, Biochemical and Biophysical Research Communication, pp. 482-487 (2013). [cited by applicant]